Good news for patients with chronic diseases!

Recently, Sanofi China announced that two of the company's drugs in the field of cardiovascular diseases, the original clopidogrel (Polivi®) and the original irbesartan hydrochlorothiazide (Ambonol®), have been successfully included in the Guangdong Alliance's procurement list

The inter-provincial drug procurement alliance led by Guangdong Province covers Guangdong, Shanxi, Henan, Hunan, Guangxi, Xinjiang and other provinces, and is currently one of the largest local centralized procurement alliances

Professor Dong Yugang, director of the Department of Cardiovascular Medicine of the First Affiliated Hospital of Sun Yat-sen University, pointed out: “The centralized procurement of medicines has brought tangible benefits to the masses, and patients can afford and buy high-quality drugs

Clopidogrel is used for the treatment of myocardial infarction, ischemic stroke, peripheral arterial disease and acute coronary syndrome (ACS); irbesartan and hydrochlorothiazide are used for the treatment of essential hypertension

Liu Jing, general manager of Sanofi's China Innovation and Core Business Department, said: "Deeply cultivating the Chinese market for nearly 40 years, Sanofi has always adhered to the patient-centered concept and escorted the health of the Chinese people with high-quality drugs and services

At present, cardiovascular disease has become a major type of disease that seriously threatens the health of Chinese residents, and is a major health problem that affects the country's economic and social development

Reference: National Center for Cardiovascular Diseases.